PMID- 34393486 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220425 IS - 1176-6336 (Print) IS - 1178-203X (Electronic) IS - 1176-6336 (Linking) VI - 17 DP - 2021 TI - To Find Out the Relationship Between Levels of Glycosylated Hemoglobin with Meibomian Gland Dysfunction in Patients with Type 2 Diabetes. PG - 797-807 LID - 10.2147/TCRM.S324423 [doi] AB - AIM: The aim of this study was to investigate the relationship between levels of glycosylated hemoglobin (HbA1c) with meibomian gland dysfunction (MGD) in patients with type 2 diabetes mellitus (T2DM) and to further explore the related influencing factors. METHODS: Totally, 167 patients with T2DM and 68 non-diabetic subjects were selected. Further, T2DM patients were divided into 2 groups based on 7% HbA1c. Standard patient evaluation of eye dryness (SPEED), lipid layer thickness (LLT), partial blink (PB) ratio, percentage of partial glands (MGP), meibomian gland yielding liquid secretion (MGYLS), meibomian gland yielding secretion score (MGYSS), line of marx (LOM), tear break up time (TBUT), tear meniscus height (TMH) and Schirmer I test (SIT) were applied to evaluate meibomian gland function. Finally, the correlation between HbA1c and various indicators was also analyzed. RESULTS: Between HbA1c>/=7% group and HbA1c<7% group, the differences in LLT (P=0.003), MGP (P<0.001), MGYLS (P=0.014) and TBUT (P=0.015) were all statistically significant. Compared with the non-diabetic group, LLT (P=0.020), MBP (P<0.001), MGYS (P< 0.001), TBUT (P<0.001), SIT (P=0.001), TMH (P=0.017) and LOM (P<0.001) were significantly different in HbA1c>/=7% group, while the differences of MBP (P=0.031), MGYSS (P<0.001), SIT (P=0.001) and LOM (P<0.001) in HbA1c/=7% group was evidently higher than that in non-diabetic group (P=0.002). Correlation analysis showed that HbA1c was significantly associated with the LTT and MGP. CONCLUSION: HbA1c>/=7% is likely to result in meibomian gland function dysfunctions in T2DM patients, especially related to LLT and MGP. CI - (c) 2021 Fan et al. FAU - Fan, Fang AU - Fan F AD - Department of Ophthalmology, Hebei General Hospital, Shijiazhuang, 050051, People's Republic of China. FAU - Li, Xiaodan AU - Li X AD - Department of Ophthalmology, Shijiazhuang People's Hospital, Shijiazhuang, 050000, People's Republic of China. FAU - Li, Kejun AU - Li K AD - Department of Ophthalmology, Hebei General Hospital, Shijiazhuang, 050051, People's Republic of China. FAU - Jia, Zhiyang AU - Jia Z AD - Department of Ophthalmology, Hebei General Hospital, Shijiazhuang, 050051, People's Republic of China. LA - eng PT - Journal Article DEP - 20210806 PL - New Zealand TA - Ther Clin Risk Manag JT - Therapeutics and clinical risk management JID - 101253281 PMC - PMC8355550 OTO - NOTNLM OT - diabetes mellitus OT - glycosylated hemoglobin OT - lipid layer thickness OT - percentage of partial glands OT - type 2 diabetes mellitus COIS- The authors declare that they have no conflict of interests. EDAT- 2021/08/17 06:00 MHDA- 2021/08/17 06:01 PMCR- 2021/08/06 CRDT- 2021/08/16 05:43 PHST- 2021/06/11 00:00 [received] PHST- 2021/07/21 00:00 [accepted] PHST- 2021/08/16 05:43 [entrez] PHST- 2021/08/17 06:00 [pubmed] PHST- 2021/08/17 06:01 [medline] PHST- 2021/08/06 00:00 [pmc-release] AID - 324423 [pii] AID - 10.2147/TCRM.S324423 [doi] PST - epublish SO - Ther Clin Risk Manag. 2021 Aug 6;17:797-807. doi: 10.2147/TCRM.S324423. eCollection 2021.